AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused ...

CHANTILLY, Va., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sealing Technologies (SealingTech), a Parsons Corporation company (NYSE: PSN), and leading defensive cyber operations solution provider, received an ...

The United Kingdom and Norway have signed a major defense agreement to protect from Russian submarines and potential attacks on submarine cables. The combined fleet of at least 13 warships will “hunt ...

LONDON (AP) — Britain and Norway will mount joint naval patrols to protect undersea cables from Russia, the U.K. said Thursday, as Prime Minister Keir Starmer and Norwegian counterpart Jonas Gahr ...

Hoth continues to advance HT-001 in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, a significant unmet need in oncology supportive care. Recent progress includes: ...

Complete GLP toxicology and CMC packages; submit IND. Initiate Phase 1/2 dose-escalation/expansion study in advanced systemic mastocytosis and other KIT-driven tumors with translational biomarkers of ...

BOCA RATON, Fla.--(BUSINESS WIRE)--SurGenTec®, a leading innovator in minimally invasive orthopedic and spine surgery solutions, is proud to announce the launch of its new TiLINK®-INSITE™ Sacroiliac ...

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...

Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours. Decreased ...

NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic ...